| Catalog No. | HW305026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Vascular Endothelial Growth Factor Receptor 3 fusion protein with IgG1 Fc Fragment. |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Vascular endothelial growth factor C, VEGFC, Flt4-L, VEGF-C, Vascular endothelial growth factor-related protein, VRP, Flt4 ligand, Vascular endothelial growth factor D, VEGF-D, FIGF, VEGFD, c-Fos-induced growth factor |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P49767 & O43915 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | OPT-302,solubleVEGFR-3,sozinibercept,VGX-300 |
|---|
| Background | Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
